ICU Medical, Inc. (NASDAQ:ICUI) Receives $175.67 Consensus Price Target from Brokerages

Shares of ICU Medical, Inc. (NASDAQ:ICUI) have received a consensus recommendation of “Moderate Buy” from the five ratings firms that are currently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell rating, one has given a hold rating, two have issued a buy rating and one has given a strong buy rating to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $175.6667.

Several brokerages recently issued reports on ICUI. Weiss Ratings reiterated a “sell (d-)” rating on shares of ICU Medical in a research note on Wednesday, October 8th. Wall Street Zen downgraded ICU Medical from a “buy” rating to a “hold” rating in a research note on Sunday. KeyCorp increased their price target on ICU Medical from $173.00 to $175.00 and gave the company an “overweight” rating in a research note on Friday, November 7th. Finally, Piper Sandler lifted their price objective on shares of ICU Medical from $153.00 to $172.00 and gave the stock an “overweight” rating in a research report on Friday, November 7th.

ICU Medical Trading Up 0.2%

Shares of ICU Medical stock opened at $148.52 on Monday. The stock has a market cap of $3.67 billion, a P/E ratio of -479.08 and a beta of 0.80. The company has a quick ratio of 1.19, a current ratio of 2.45 and a debt-to-equity ratio of 0.62. ICU Medical has a 12-month low of $107.00 and a 12-month high of $175.51. The business’s 50 day moving average is $144.54 and its 200-day moving average is $131.84.

ICU Medical (NASDAQ:ICUI) last issued its earnings results on Thursday, November 6th. The medical instruments supplier reported $2.03 earnings per share for the quarter, topping analysts’ consensus estimates of $1.43 by $0.60. ICU Medical had a negative net margin of 0.32% and a positive return on equity of 7.71%. The business had revenue of $533.30 million for the quarter, compared to the consensus estimate of $511.46 million. During the same period in the previous year, the company earned $1.59 earnings per share. The firm’s revenue for the quarter was down 8.9% on a year-over-year basis. ICU Medical has set its FY 2025 guidance at 7.350-7.650 EPS. Equities research analysts predict that ICU Medical will post 4.11 earnings per share for the current fiscal year.

Insider Activity at ICU Medical

In other news, Director Elisha W. Finney sold 1,285 shares of the business’s stock in a transaction that occurred on Tuesday, November 11th. The stock was sold at an average price of $140.42, for a total transaction of $180,439.70. Following the completion of the sale, the director owned 3,995 shares in the company, valued at $560,977.90. The trade was a 24.34% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, VP Virginia Ruth Sanzone sold 930 shares of the stock in a transaction that occurred on Tuesday, November 11th. The stock was sold at an average price of $142.34, for a total value of $132,376.20. Following the transaction, the vice president owned 5,456 shares in the company, valued at approximately $776,607.04. This trade represents a 14.56% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 1.50% of the company’s stock.

Hedge Funds Weigh In On ICU Medical

A number of hedge funds have recently bought and sold shares of ICUI. Cullen Frost Bankers Inc. acquired a new position in shares of ICU Medical during the 2nd quarter worth approximately $38,000. SJS Investment Consulting Inc. grew its position in ICU Medical by 41,000.0% during the third quarter. SJS Investment Consulting Inc. now owns 411 shares of the medical instruments supplier’s stock worth $49,000 after buying an additional 410 shares in the last quarter. Covestor Ltd increased its stake in ICU Medical by 70.7% during the 3rd quarter. Covestor Ltd now owns 570 shares of the medical instruments supplier’s stock worth $68,000 after acquiring an additional 236 shares during the period. Blue Trust Inc. increased its stake in ICU Medical by 17.6% during the 2nd quarter. Blue Trust Inc. now owns 942 shares of the medical instruments supplier’s stock worth $124,000 after acquiring an additional 141 shares during the period. Finally, Smartleaf Asset Management LLC raised its holdings in ICU Medical by 11.6% in the 2nd quarter. Smartleaf Asset Management LLC now owns 969 shares of the medical instruments supplier’s stock valued at $128,000 after acquiring an additional 101 shares in the last quarter. 96.10% of the stock is owned by institutional investors.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.